Oncotelic Therapeutics, Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)
Oncotelic Therapeutics, Inc. (OTLC) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) of -$12.79 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease · last filed 2026-08-13
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for the quarter ending 2026-06-30 was -$102.87K.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for the quarter ending 2026-03-31 was $90.08K, a 51.73% increase year-over-year.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for the quarter ending 2025-12-31 was -$320.80K, a 176.16% decline year-over-year.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for the quarter ending 2025-09-30 was $392.06K.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for fiscal 2024 was $280.40K, a 24.58% increase from fiscal 2023.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for fiscal 2023 was $225.07K.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for fiscal 2022 was -$142.15K.
- Oncotelic Therapeutics, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, period increase (decrease) for fiscal 2021 was -$292.15K, a 748.49% decline from fiscal 2020.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 12 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$102.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$12.79K 10-Q · filed 2026-08-13 | -$333.59K derived: sum of 3 quarters · filed 2026-08-13 | $58.47K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $90.08K 10-Q · filed 2026-05-14 | -$230.72K derived: sum of 2 quarters · filed 2026-08-13 | $161.34K derived: sum of 3 quarters · filed 2026-08-13 | -$322.86K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$320.80K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-13 | $71.26K derived: sum of 2 quarters · filed 2026-08-13 | -$412.94K derived: sum of 3 quarters · filed 2026-08-13 | -$353.57K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $392.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | -$92.14K derived: sum of 2 quarters · filed 2025-11-17 | -$32.77K 10-Q · filed 2025-11-17 | $388.46K derived: sum of 4 quarters · filed 2026-04-15 | |
| 2025-06-30 | -$484.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$424.83K 10-Q · filed 2025-08-13 | -$3.60K derived: sum of 3 quarters · filed 2026-04-15 | -$118.32K derived: sum of 4 quarters · filed 2026-04-15 | |
| 2025-03-31 | $59.37K 10-Q · filed 2025-05-15 | $480.60K derived: sum of 2 quarters · filed 2026-04-15 | $365.88K derived: sum of 3 quarters · filed 2026-04-15 | $342.25K derived: sum of 4 quarters · filed 2026-04-15 | |
| 2024-12-31 | $421.23K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $306.51K derived: sum of 2 quarters · filed 2026-04-15 | $282.88K derived: sum of 3 quarters · filed 2026-04-15 | $280.40K 10-K · filed 2026-04-15 | $280.40K 10-K · filed 2025-04-15 |
| 2024-09-30 | -$114.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-19 | -$138.35K derived: sum of 2 quarters · filed 2024-11-19 | -$140.83K 10-Q · filed 2024-11-19 | $63.49K derived: sum of 4 quarters · filed 2025-04-15 | |
| 2024-06-30 | -$23.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$26.11K 10-Q · filed 2024-08-14 | $178.21K derived: sum of 3 quarters · filed 2025-04-15 | -$128.63K derived: sum of 4 quarters · filed 2025-04-15 | |
| 2024-03-31 | -$2.48K 10-Q · filed 2024-05-15 | $201.84K derived: sum of 2 quarters · filed 2025-04-15 | -$105.00K derived: sum of 3 quarters · filed 2025-04-15 | $202.70K derived: sum of 4 quarters · filed 2025-04-15 | |
| 2023-12-31 | $204.32K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$102.52K derived: sum of 2 quarters · filed 2025-04-15 | $205.18K derived: sum of 3 quarters · filed 2025-04-15 | $225.07K 10-K · filed 2025-04-15 | |
| 2023-09-30 | -$306.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $862.00 derived: sum of 2 quarters · filed 2023-11-14 | $20.76K 10-Q · filed 2023-11-14 | -$83.65K derived: sum of 4 quarters · filed 2024-04-12 | |
| 2023-06-30 | $307.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-18 | $327.59K 10-Q · filed 2023-08-18 | $223.18K derived: sum of 3 quarters · filed 2024-04-12 | $117.52K derived: sum of 4 quarters · filed 2024-04-12 | |
| 2023-03-31 | $19.90K 10-Q · filed 2023-05-22 | -$84.51K derived: sum of 2 quarters · filed 2024-04-12 | -$190.18K derived: sum of 3 quarters · filed 2024-04-12 | -$313.10K derived: sum of 4 quarters · filed 2024-04-12 | |
| 2022-12-31 | -$104.41K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-12 | -$210.07K derived: sum of 2 quarters · filed 2024-04-12 | -$332.99K derived: sum of 3 quarters · filed 2024-04-12 | -$142.15K 10-K · filed 2024-04-12 | |
| 2022-09-30 | -$105.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-18 | -$228.58K derived: sum of 2 quarters · filed 2023-08-18 | -$37.74K 10-Q · filed 2022-11-18 | -$90.61K derived: sum of 4 quarters · filed 2023-08-18 | |
| 2022-06-30 | -$122.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-18 | $67.92K 10-Q · filed 2023-08-18 | $15.05K derived: sum of 3 quarters · filed 2023-08-18 | -$130.40K derived: sum of 4 quarters · filed 2023-08-18 | |
| 2022-03-31 | $190.84K 10-Q · filed 2023-05-22 | $137.97K derived: sum of 2 quarters · filed 2023-05-22 | -$7.48K derived: sum of 3 quarters · filed 2023-05-22 | -$637.65K derived: sum of 4 quarters · filed 2023-05-22 | |
| 2021-12-31 | -$52.87K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-20 | -$198.32K derived: sum of 2 quarters · filed 2023-04-20 | -$828.49K derived: sum of 3 quarters · filed 2023-04-20 | -$292.15K 10-K/A · filed 2023-04-20 | |
| 2021-09-30 | -$145.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-18 | -$775.62K derived: sum of 2 quarters · filed 2022-11-18 | -$239.28K 10-Q · filed 2022-11-18 | -$133.72K derived: sum of 4 quarters · filed 2022-11-18 | |
| 2021-06-30 | -$630.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-22 | -$93.83K 10-Q · filed 2022-08-22 | $11.73K derived: sum of 3 quarters · filed 2022-08-22 | -$38.27K derived: sum of 4 quarters · filed 2022-08-22 | |
| 2021-03-31 | $536.35K 10-Q · filed 2022-05-23 | $641.90K derived: sum of 2 quarters · filed 2022-05-23 | $591.91K derived: sum of 3 quarters · filed 2022-05-23 | -$154.90K derived: sum of 4 quarters · filed 2022-05-23 | |
| 2020-12-31 | $105.56K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-15 | $55.56K derived: sum of 2 quarters · filed 2022-04-15 | -$691.25K derived: sum of 3 quarters · filed 2022-04-15 | $45.05K 10-K · filed 2022-04-15 | |
| 2020-09-30 | -$49.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-22 | -$796.80K derived: sum of 2 quarters · filed 2021-11-22 | -$60.50K 10-Q · filed 2021-11-22 | ||
| 2020-06-30 | -$746.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-20 | -$10.51K 10-Q · filed 2021-08-20 | |||
| 2020-03-31 | $736.30K 10-Q · filed 2021-05-24 | ||||
| 2019-12-31 | -$191.64K 10-K · filed 2021-04-15 |